A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)
Not Applicable
Completed
- Conditions
- Healthy
- Interventions
- Device: Next Generation Diagnostic Instrument (NGDI)Device: Zyoptix Diagnostic Workstation (ZDW)
- Registration Number
- NCT00347594
- Lead Sponsor
- Bausch & Lomb Incorporated
- Brief Summary
The purpose of this study is to measure the aberrations, corneal surface topography and pachymetry of normal human eyes with the NGDI.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 76
Inclusion Criteria
- +10.00D to -20.00D of absolute spherical ametropia
- Must be part of the Bausch & Lomb research clinic
- Snellen visual acuity must be correctable to 20/25
Exclusion Criteria
- No more than -6.00D of refractive astigmatism
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Next Generation Diagnostic Instrument Next Generation Diagnostic Instrument (NGDI) Next Generation Diagnostic Instrument (NGDI) Zyoptix Diagnostic Workstation Zyoptix Diagnostic Workstation (ZDW) Zyoptix Diagnostic Workstation (ZDW)
- Primary Outcome Measures
Name Time Method Measurement of aberrations with the NGDI and the Zywave II. Single visit
- Secondary Outcome Measures
Name Time Method Measurement of corneal topography and pachymetry with the NGDI and the Orbscan IIz. Single visit
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does NGDI's wavefront aberrometry compare to traditional corneal topography in measuring ocular aberrations?
What are the clinical advantages of Zyoptix Diagnostic Workstation over standard pachymetry devices in healthy eyes?
Which corneal biomarkers correlate with NGDI's diagnostic accuracy in normal human eyes?
What adverse events were reported during NGDI evaluation in NCT00347594 and how were they managed?
How does Bausch & Lomb's NGDI technology compare to competitor devices like Zywave or Pentacam in ophthalmic diagnostics?
Trial Locations
- Locations (1)
Bausch & Lomb
🇺🇸Rochester, New York, United States